209 related articles for article (PubMed ID: 12243078)
1. [Prostatic cancer with multiple pulmonary metastases treated successfully with hormonal therapy: a case report].
Fukuda M; Takashima H; Fuse H; Hirano S
Hinyokika Kiyo; 2002 Aug; 48(8):499-502. PubMed ID: 12243078
[TBL] [Abstract][Full Text] [Related]
2. [Successful complete androgen blockade (CAB) therapy for prostatic cancer detected from multiple lung metastases: a case report].
Tokumitsu M; Inada F; Kitahara K; Kawakami N; Masui N; Ishida H; Ishida H; Saga Y; Hashimoto H; Yachiku S
Hinyokika Kiyo; 2001 Jan; 47(1):59-62. PubMed ID: 11235226
[TBL] [Abstract][Full Text] [Related]
3. [A case of prostatic cancer discovered from lung metastatic lesions].
Segawa N; Abe H; Nishida T; Katsuoka Y
Hinyokika Kiyo; 2006 Feb; 52(2):147-9. PubMed ID: 16541771
[TBL] [Abstract][Full Text] [Related]
4. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy.
Diamond T; Campbell J; Bryant C; Lynch W
Cancer; 1998 Oct; 83(8):1561-6. PubMed ID: 9781950
[TBL] [Abstract][Full Text] [Related]
5. [A case of prostate cancer treated with combined androgen-blockade].
Kurita M; Kato Y; Tamura Y; Suzuki K; Yamanaka H
Gan To Kagaku Ryoho; 2000 Feb; 27(2):307-10. PubMed ID: 10700907
[TBL] [Abstract][Full Text] [Related]
6. Does small-cell phenotype predict the natural history of prostate cancer? A case study in disease behavior.
Slovin SF
Nat Clin Pract Oncol; 2007 Sep; 4(9):551-4. PubMed ID: 17728713
[TBL] [Abstract][Full Text] [Related]
7. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
8. [Prostatic cancer with cystic formation: a case report].
Kubo M; Taguchi K; Fujisue H; Ihara H; Ikoma F
Hinyokika Kiyo; 1998 Dec; 44(12):883-6. PubMed ID: 10028435
[TBL] [Abstract][Full Text] [Related]
9. The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study.
Diamond TH; Winters J; Smith A; De Souza P; Kersley JH; Lynch WJ; Bryant C
Cancer; 2001 Sep; 92(6):1444-50. PubMed ID: 11745221
[TBL] [Abstract][Full Text] [Related]
10. Flutamide withdrawal plus hydrocortisone resulted in clinical complete response in a patient with prostate carcinoma.
Figg WD; Kroog G; Duray P; Walther MM; Patronas N; Sartor O; Reed E
Cancer; 1997 May; 79(10):1964-8. PubMed ID: 9149024
[TBL] [Abstract][Full Text] [Related]
11. Prior administration of a non-steroidal anti-androgen failed to prevent the flare-up caused by a luteinizing hormone-releasing hormone agonist in a patient with metastatic prostate cancer.
Uehara S; Yuasa T; Fujii Y; Yano A; Yamamoto S; Masuda H; Fukui I; Yonese J
BMC Res Notes; 2015 Aug; 8():335. PubMed ID: 26242866
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer with multiple lung metastases in a hemodialysis patient.
Hayakawa K; Matsumoto M; Aoyagi T; Miyaji K; Hata M
Int J Urol; 2000 Dec; 7(12):464-6. PubMed ID: 11168686
[TBL] [Abstract][Full Text] [Related]
13. Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: insight into mechanisms?
Daskivich TJ; Oh WK
Urology; 2006 May; 67(5):1084.e15-7. PubMed ID: 16698377
[TBL] [Abstract][Full Text] [Related]
14. Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial.
de Leval J; Boca P; Yousef E; Nicolas H; Jeukenne M; Seidel L; Bouffioux C; Coppens L; Bonnet P; Andrianne R; Wlatregny D
Clin Prostate Cancer; 2002 Dec; 1(3):163-71. PubMed ID: 15046691
[TBL] [Abstract][Full Text] [Related]
15. [Intermittent androgen deprivation treatment of prostate cancer restarted at low level of serum prostate specific antigen: a pilot study].
Maekawa S; Maegawa M; Ushida H; Inoue K; Kaneko Y; Ohmori K; Nishimura K
Hinyokika Kiyo; 2001 Aug; 47(8):553-5. PubMed ID: 11579594
[TBL] [Abstract][Full Text] [Related]
16. Metastatic prostate cancer pulmonary nodules: beneficial effects of combination therapy and subsequent withdrawal of flutamide.
Cusan L; Gomez JL; Dupont A; Diamond P; Lemay M; Moore S; Labrie F
Prostate; 1994 May; 24(5):257-61. PubMed ID: 7513417
[TBL] [Abstract][Full Text] [Related]
17. [A case of locally advanced prostate cancer with low serum testosterone associated with intake of an androgenic medicine].
Sakura M; Tsukamoto T; Yonese J; Nakaishi M; Maezawa T; Takimoto K; Fukui I
Nihon Hinyokika Gakkai Zasshi; 2003 May; 94(4):529-32. PubMed ID: 12795169
[TBL] [Abstract][Full Text] [Related]
18. Orbital metastasis as a first indication of prostate cancer: a case report.
Autorino R; Zito A; Di Giacomo F; Cosentino L; Quarto G; Di Lorenzo G; Mordente S; Pane U; Giordano A; D'Armiento M
Arch Ital Urol Androl; 2005 Jun; 77(2):109-10. PubMed ID: 16146273
[TBL] [Abstract][Full Text] [Related]
19. Characterization of patients with androgen-independent prostatic carcinoma whose serum prostate specific antigen decreased following flutamide withdrawal.
Herrada J; Dieringer P; Logothetis CJ
J Urol; 1996 Feb; 155(2):620-3. PubMed ID: 8558675
[TBL] [Abstract][Full Text] [Related]
20. A pilot study of intermittent androgen ablation in advanced prostate cancer in Japanese men.
Egawa S; Takashima R; Matsumoto K; Mizoguchi H; Kuwao S; Baba S
Jpn J Clin Oncol; 2000 Jan; 30(1):21-6. PubMed ID: 10770564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
